xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05974111</url>
    </required_header>
    <id_info>
      <org_study_id>Z-2022142</org_study_id>
      <nct_id>NCT05974111</nct_id>
    </id_info>
    <brief_title>COAgulation Disorders in Ischaemic and Haemorrhagic Stroke</brief_title>
    <acronym>COADIHS</acronym>
    <official_title>COAgulation Disorders in Ischaemic and Haemorrhagic Stroke</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Ziekenhuis Oost-Limburg</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>Synapse bv</agency>
        <agency_class>Industry</agency_class>
      </collaborator>
    </sponsors>
    <source>Ziekenhuis Oost-Limburg</source>
    <oversight_info>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        In this study the investigators will assess both procoagulant and anticoagulant pathways&#xD;
        using thrombin generation and platelet function tests in all patients presenting with&#xD;
        ischaemic and haemorrhagic stroke (including aneurysmal subarachnoid haemorraghe). Also the&#xD;
        cross-talk between inflammation and thrombosis, so-called thrombo-inflammation is further&#xD;
        investigated. As such the investigators aim to characterise the patient's coagulation profile&#xD;
        before administration of any treatment. By assessing these pathways the investigators strive&#xD;
        to detect specific markers to predict vital and functional outcome at 3 months in these&#xD;
        patients. Finally the investigators may provide new pathophysiological insights in the course&#xD;
        of disease following these events that can possibly improve future therapeutic strategies.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        In the COADIHS trial the main objective is to map the coagulation profile, both procoagulant&#xD;
        and anticoagulant pathways, in patients presenting with acute ischaemic or haemorrhagic&#xD;
        stroke.&#xD;
  &#xD;
        By assessing these different pathways the investigators aim to detect possible biomarkers of&#xD;
        coagulation with predictive value for functional and vital outcome at 3 months.&#xD;
  &#xD;
        In different subgroup analyses the investigators try to answer additional research questions&#xD;
        as posed by the specific pathophysiology.&#xD;
  &#xD;
        Primary Objective:&#xD;
  &#xD;
        Mapping the coagulation profile of both procoagulant and anticoagulant pathways together with&#xD;
        markers of inflammation in patients presenting with all types of acute ischaemic or&#xD;
        haemorrhagic stroke, at presentation and during first 7 days of clinical course in order to&#xD;
        detect biochemical markers with predictive value of vital and functional outcome at 3 months.&#xD;
  &#xD;
        Secondary Objective:&#xD;
  &#xD;
          -  Detection of culprit underlying thrombophilia in cryptogenic stroke and evaluation of&#xD;
             their effect on clinical course and outcome (recurrent stroke).&#xD;
  &#xD;
          -  Evaluating the interaction between the coagulation profile and pre-stroke medication&#xD;
             that works on coagulation pathways.&#xD;
  &#xD;
          -  To investigate the role of platelets and platelet activation in different&#xD;
             pathophysiological mechanisms described in development of delayed cerebral ischemia&#xD;
             following aneurysmal subarachnoid haemorrhage (aSAH)(microvessel constriction,&#xD;
             thromboinflammation, large artery vasospasm, cortical spreading depolarization)&#xD;
  &#xD;
          -  To evaluate the role of haemostatic derangements following aSAH as biomarker to predict&#xD;
             delayed cerebral ischemia.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Recruiting</overall_status>
    <start_date type="Actual">May 2, 2023</start_date>
    <completion_date type="Anticipated">August 31, 2025</completion_date>
    <primary_completion_date type="Anticipated">May 2, 2025</primary_completion_date>
    <study_type>Observational</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <observational_model>Cohort</observational_model>
      <time_perspective>Prospective</time_perspective>
    </study_design_info>
    <primary_outcome>
      <measure>Functional Outcome Modified rankin scale</measure>
      <time_frame>3 months</time_frame>
      <description>Modified Rankin Scale as defined by:&#xD;
  score 0: no symptoms score 1: No significant disability despite symptoms; able to carry out all usual duties and activities Score 2:Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance Score 3: Moderate disability; requiring some help, but able to walk without assistance Score 4:Moderately severe disability; unable to walk and attend to bodily needs without assistance Score 5: Severe disability; bedridden, incontinent and requiring constant nursing care and attention Score 6:Dead&#xD;
  With Score 3-6 defined as poor outcome and score 0-2 defined as good outcome</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Functional Outcome recurrent stroke</measure>
      <time_frame>3 months</time_frame>
      <description>Recurrent stroke during first 3 months</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Vital Outcome - all cause mortality</measure>
      <time_frame>3 months</time_frame>
      <description>Mortality rate in the participants of all cause at 3 months</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>ICU Length of stay</measure>
      <time_frame>3 months</time_frame>
      <description>duration (days)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Hospital Length of stay</measure>
      <time_frame>3 months</time_frame>
      <description>duration (days)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Need for mechanical ventilation in ICU</measure>
      <time_frame>3 months</time_frame>
      <description>Yes/No and duration (days)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Need for renal replacement therapy in ICU</measure>
      <time_frame>3 months</time_frame>
      <description>YES / NO and duration (days)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Deep vein thrombosis</measure>
      <time_frame>3 months</time_frame>
      <description>Yes/No</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Need for ventriculo-external drain / ventriculo-peritoneal drain</measure>
      <time_frame>3 months</time_frame>
      <description>Yes / No</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Rate of delayed cerebral ischemia participants with aneurysmal subarachnoid haemorrhage</measure>
      <time_frame>3 months</time_frame>
      <description>Rate of delayed cerebral ischemia in participants with aneurysmal subarachnoid haemorrhage&#xD;
  vasospasm: clinical / radiological (transcranial doppler, CT perfusion, MRI)&#xD;
  Delayed cerebral ischemia as diagnosed with MRI</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Need for decompressive craniectomy</measure>
      <time_frame>3 months</time_frame>
      <description>Yes / no</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Haemorrhagic transformation of infarction</measure>
      <time_frame>3 months</time_frame>
      <description>yes / No</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Rebleeding aneurysm in aneurysmal subarachnoid haemorrhage</measure>
      <time_frame>3 months</time_frame>
      <description>yes /no</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Rate of epilepsy</measure>
      <time_frame>3 months</time_frame>
      <description>Both convulsive epileptic episode as non-convulsive epileptic episode. Both clinical diagnosis and elektro-encephalogram</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Rate of infection in participants</measure>
      <time_frame>3 months</time_frame>
      <description>CNS infection, Pulmonary infection, genito-urinary infection, catheter related blood stream infection,gastro-intestinal infection, skin infection, other infection, bacteriemia, fungaemia</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Rate of Intensive Care Aquired weakness (ICUAW)</measure>
      <time_frame>3 months</time_frame>
      <description>critical illness myopathy, critical illness polyneuropathy or icu-AW</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Rate of diabetes insipidus during first week</measure>
      <time_frame>7days</time_frame>
      <description>Diabetes insipidus</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Rate of cardiovascular compromise during first week</measure>
      <time_frame>7 days</time_frame>
      <description>As defined by use of vasopressors and inotropes / acute heart failure / acute myocardial infarction / cardiac arrest / new arrythmia / use of VA-ECMO</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Rate of acute respiratory failure during first week</measure>
      <time_frame>7 days</time_frame>
      <description>acute respiratory failure (intubation + mechanical ventilation / non-invasive ventilation / ARDS), need for VV-ECMO / neurogenic pulmonary edema</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Rate of Acute kidney injury during first week</measure>
      <time_frame>7 days</time_frame>
      <description>acute kidney injury (KDIGO classification)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Rate of enteral feeding (oral/nasograstic) or Total parenteral nutrition during first week</measure>
      <time_frame>7 days</time_frame>
      <description>TPN / enteral feeding (oral/nastrogastric)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Rate of Acute liver failure during first week</measure>
      <time_frame>7 days</time_frame>
      <description>Acute liver failure&#xD;
  INR &gt; 1.5&#xD;
  Any grade of hepatic encefalopathy&#xD;
  No prior evidence of liver disease</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Rate of infection during first week</measure>
      <time_frame>7 days</time_frame>
      <description>CNS infection / pulmonary infection / endocarditis / UTI / GI infection /skin infection / blood stream infection</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Rate of antiplatelet / anticoagulant therapy during first week</measure>
      <time_frame>7 days</time_frame>
      <description>Rate of antiplatelet therapy or anticoagulant therapy in participants</description>
    </secondary_outcome>
    <number_of_groups>3</number_of_groups>
    <enrollment type="Anticipated">350</enrollment>
    <condition>Ischemic Stroke</condition>
    <condition>Haemorrhagic Stroke</condition>
    <condition>Aneurysmal Subarachnoid Hemorrhage</condition>
    <arm_group>
      <arm_group_label>Ischemic Stroke</arm_group_label>
      <description>Patients presenting at emergency department / Intensive Care unit with ischemic stroke&#xD;
  registration of baseline clinical data&#xD;
  registration of baseline blood parameters (in context of standard of clinical care)&#xD;
  additional blood sampling at 4 time points during 1st week with the purpose of full coagulation testing</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Haemorrhagic stroke</arm_group_label>
      <description>Patients presenting at emergency department / Intensive Care unit with haemorraghic stroke (spontaneous intracranial bleeding, no trauma)&#xD;
  registration of baseline clinical data&#xD;
  registration of baseline blood parameters (in context of standard of clinical care)&#xD;
  additional blood sampling at 4 time points during 1st week with the purpose of full coagulation testing</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Aneursmal Subarachnoid Haemorrhage</arm_group_label>
      <description>Patients presenting at emergency department / Intensive Care unit with aneurysmal subarachnoid haemorrhage&#xD;
  registration of baseline clinical data&#xD;
  registration of baseline blood parameters (in context of standard of clinical care)&#xD;
  additional blood sampling at 4 time points during 1st week with the purpose of full coagulation testing</description>
    </arm_group>
    <intervention>
      <intervention_type>Diagnostic Test</intervention_type>
      <intervention_name>blood sampling</intervention_name>
      <description>At 4 time points (D0,D3,D5,D7) blood samples will be drawn next to blood sampling in context of standard of clinical care. A full coagulation and inflammation profile will be obtained.</description>
      <arm_group_label>Aneursmal Subarachnoid Haemorrhage</arm_group_label>
      <arm_group_label>Haemorrhagic stroke</arm_group_label>
      <arm_group_label>Ischemic Stroke</arm_group_label>
    </intervention>
    <biospec_retention>Samples Without DNA</biospec_retention>
    <biospec_descr>
      <textblock>
        Blood samples stored in biobank for full coagulation testing&#xD;
      </textblock>
    </biospec_descr>
    <eligibility>
      <study_pop>
        <textblock>
          The study population will consist of patients presenting at the hospital with ischaemic&#xD;
          stroke, transient ischaemic attack, haemorrhagic stroke or aneurysmal subarachnoid&#xD;
          haemorrhage.&#xD;
  &#xD;
          As our hospital is a referral centre, both referred patients and patients presenting at our&#xD;
          emergency department will be screened for eligibility.&#xD;
        </textblock>
      </study_pop>
      <sampling_method>Probability Sample</sampling_method>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
          Presenting at the hospital with ischaemic stroke, transient ischaemic attack, haemorrhagic&#xD;
          stroke, aneurysmal subarachnoid haemorrhage or any other type of non-traumatic,&#xD;
          intracranial bleeding&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Refusal of participation by patient or legal representative&#xD;
  &#xD;
            -  Traumatic intracranial (subdural, subarachnoid, epidural haematoma) bleeding&#xD;
  &#xD;
            -  Patientes receiving treatment with interference on coagulation (pro / anti) before&#xD;
               first sampling&#xD;
  &#xD;
            -  Patients with a National Institutes Of Health Stroke Scale &lt; 4 will be excluded from&#xD;
               analysis afterwards&#xD;
  &#xD;
            -  Patients categorized as having stroke mimic will be excluded from analysis afterwards&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
    </eligibility>
    <overall_official>
      <last_name>Hendrik Stragier, MD</last_name>
      <role>Principal Investigator</role>
      <affiliation>Ziekenhuis Oost-Limburg</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Hendrik Stragier, MD</last_name>
      <phone>+3289325277</phone>
      <email>hendrik.stragier@zol.be</email>
    </overall_contact>
    <location>
      <facility>
        <name>Ziekenhuis Oost-Limburg</name>
        <address>
          <city>Genk</city>
          <zip>3600</zip>
          <country>Belgium</country>
        </address>
      </facility>
      <status>Recruiting</status>
      <contact>
        <last_name>Hendrik Stragier, MD</last_name>
        <phone>+3289325277</phone>
        <email>hendrik.stragier@zol.be</email>
      </contact>
    </location>
    <location_countries>
      <country>Belgium</country>
    </location_countries>
    <verification_date>May 2023</verification_date>
    <study_first_submitted>May 30, 2023</study_first_submitted>
    <study_first_submitted_qc>July 25, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 3, 2023</study_first_posted>
    <last_update_submitted>July 25, 2023</last_update_submitted>
    <last_update_submitted_qc>July 25, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 3, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Stroke</mesh_term>
      <mesh_term>Ischemic Stroke</mesh_term>
      <mesh_term>Subarachnoid Hemorrhage</mesh_term>
      <mesh_term>Hemorrhagic Stroke</mesh_term>
      <mesh_term>Hemostatic Disorders</mesh_term>
      <mesh_term>Blood Coagulation Disorders</mesh_term>
      <mesh_term>Ischemia</mesh_term>
      <mesh_term>Hemorrhage</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>No</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05974111
  org study id: Z-2022142
  nct id: NCT05974111
  lead sponsor: 
  collaborator: 
  is fda regulated drug: No
  is fda regulated device: No
  In this study the investigators will assess both procoagulant and anticoagulant pathways
        using thrombin generation and platelet function tests in all patients presenting with
        ischaemic and haemorrhagic stroke (including aneurysmal subarachnoid haemorraghe). Also the
        cross-talk between inflammation and thrombosis, so-called thrombo-inflammation is further
        investigated. As such the investigators aim to characterise the patient's coagulation profile
        before administration of any treatment. By assessing these pathways the investigators strive
        to detect specific markers to predict vital and functional outcome at 3 months in these
        patients. Finally the investigators may provide new pathophysiological insights in the course
        of disease following these events that can possibly improve future therapeutic strategies.
  In the COADIHS trial the main objective is to map the coagulation profile, both procoagulant
        and anticoagulant pathways, in patients presenting with acute ischaemic or haemorrhagic
        stroke.
  
        By assessing these different pathways the investigators aim to detect possible biomarkers of
        coagulation with predictive value for functional and vital outcome at 3 months.
  
        In different subgroup analyses the investigators try to answer additional research questions
        as posed by the specific pathophysiology.
  
        Primary Objective:
  
        Mapping the coagulation profile of both procoagulant and anticoagulant pathways together with
        markers of inflammation in patients presenting with all types of acute ischaemic or
        haemorrhagic stroke, at presentation and during first 7 days of clinical course in order to
        detect biochemical markers with predictive value of vital and functional outcome at 3 months.
  
        Secondary Objective:
  
          -  Detection of culprit underlying thrombophilia in cryptogenic stroke and evaluation of
             their effect on clinical course and outcome (recurrent stroke).
  
          -  Evaluating the interaction between the coagulation profile and pre-stroke medication
             that works on coagulation pathways.
  
          -  To investigate the role of platelets and platelet activation in different
             pathophysiological mechanisms described in development of delayed cerebral ischemia
             following aneurysmal subarachnoid haemorrhage (aSAH)(microvessel constriction,
             thromboinflammation, large artery vasospasm, cortical spreading depolarization)
  
          -  To evaluate the role of haemostatic derangements following aSAH as biomarker to predict
             delayed cerebral ischemia.
  observational model: Cohort
  time perspective: Prospective
  measure: Functional Outcome Modified rankin scale
  time frame: 3 months
  description: Modified Rankin Scale as defined by:
  score 0: no symptoms score 1: No significant disability despite symptoms; able to carry out all usual duties and activities Score 2:Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance Score 3: Moderate disability; requiring some help, but able to walk without assistance Score 4:Moderately severe disability; unable to walk and attend to bodily needs without assistance Score 5: Severe disability; bedridden, incontinent and requiring constant nursing care and attention Score 6:Dead
  With Score 3-6 defined as poor outcome and score 0-2 defined as good outcome
  measure: Functional Outcome recurrent stroke
  time frame: 3 months
  description: Recurrent stroke during first 3 months
  measure: Vital Outcome - all cause mortality
  time frame: 3 months
  description: Mortality rate in the participants of all cause at 3 months
  measure: ICU Length of stay
  time frame: 3 months
  description: duration (days)
  measure: Hospital Length of stay
  time frame: 3 months
  description: duration (days)
  measure: Need for mechanical ventilation in ICU
  time frame: 3 months
  description: Yes/No and duration (days)
  measure: Need for renal replacement therapy in ICU
  time frame: 3 months
  description: YES / NO and duration (days)
  measure: Deep vein thrombosis
  time frame: 3 months
  description: Yes/No
  measure: Need for ventriculo-external drain / ventriculo-peritoneal drain
  time frame: 3 months
  description: Yes / No
  measure: Rate of delayed cerebral ischemia participants with aneurysmal subarachnoid haemorrhage
  time frame: 3 months
  description: Rate of delayed cerebral ischemia in participants with aneurysmal subarachnoid haemorrhage
  vasospasm: clinical / radiological (transcranial doppler, CT perfusion, MRI)
  Delayed cerebral ischemia as diagnosed with MRI
  measure: Need for decompressive craniectomy
  time frame: 3 months
  description: Yes / no
  measure: Haemorrhagic transformation of infarction
  time frame: 3 months
  description: yes / No
  measure: Rebleeding aneurysm in aneurysmal subarachnoid haemorrhage
  time frame: 3 months
  description: yes /no
  measure: Rate of epilepsy
  time frame: 3 months
  description: Both convulsive epileptic episode as non-convulsive epileptic episode. Both clinical diagnosis and elektro-encephalogram
  measure: Rate of infection in participants
  time frame: 3 months
  description: CNS infection, Pulmonary infection, genito-urinary infection, catheter related blood stream infection,gastro-intestinal infection, skin infection, other infection, bacteriemia, fungaemia
  measure: Rate of Intensive Care Aquired weakness (ICUAW)
  time frame: 3 months
  description: critical illness myopathy, critical illness polyneuropathy or icu-AW
  measure: Rate of diabetes insipidus during first week
  time frame: 7days
  description: Diabetes insipidus
  measure: Rate of cardiovascular compromise during first week
  time frame: 7 days
  description: As defined by use of vasopressors and inotropes / acute heart failure / acute myocardial infarction / cardiac arrest / new arrythmia / use of VA-ECMO
  measure: Rate of acute respiratory failure during first week
  time frame: 7 days
  description: acute respiratory failure (intubation + mechanical ventilation / non-invasive ventilation / ARDS), need for VV-ECMO / neurogenic pulmonary edema
  measure: Rate of Acute kidney injury during first week
  time frame: 7 days
  description: acute kidney injury (KDIGO classification)
  measure: Rate of enteral feeding (oral/nasograstic) or Total parenteral nutrition during first week
  time frame: 7 days
  description: TPN / enteral feeding (oral/nastrogastric)
  measure: Rate of Acute liver failure during first week
  time frame: 7 days
  description: Acute liver failure
  INR > 1.5
  Any grade of hepatic encefalopathy
  No prior evidence of liver disease
  measure: Rate of infection during first week
  time frame: 7 days
  description: CNS infection / pulmonary infection / endocarditis / UTI / GI infection /skin infection / blood stream infection
  measure: Rate of antiplatelet / anticoagulant therapy during first week
  time frame: 7 days
  description: Rate of antiplatelet therapy or anticoagulant therapy in participants
  arm group label: Ischemic Stroke
  description: Patients presenting at emergency department / Intensive Care unit with ischemic stroke
  registration of baseline clinical data
  registration of baseline blood parameters (in context of standard of clinical care)
  additional blood sampling at 4 time points during 1st week with the purpose of full coagulation testing
  arm group label: Haemorrhagic stroke
  description: Patients presenting at emergency department / Intensive Care unit with haemorraghic stroke (spontaneous intracranial bleeding, no trauma)
  registration of baseline clinical data
  registration of baseline blood parameters (in context of standard of clinical care)
  additional blood sampling at 4 time points during 1st week with the purpose of full coagulation testing
  arm group label: Aneursmal Subarachnoid Haemorrhage
  description: Patients presenting at emergency department / Intensive Care unit with aneurysmal subarachnoid haemorrhage
  registration of baseline clinical data
  registration of baseline blood parameters (in context of standard of clinical care)
  additional blood sampling at 4 time points during 1st week with the purpose of full coagulation testing
  intervention type: Diagnostic Test
  intervention name: blood sampling
  description: At 4 time points (D0,D3,D5,D7) blood samples will be drawn next to blood sampling in context of standard of clinical care. A full coagulation and inflammation profile will be obtained.
  arm group label: Aneursmal Subarachnoid Haemorrhage
  arm group label: Haemorrhagic stroke
  arm group label: Ischemic Stroke
  Blood samples stored in biobank for full coagulation testing
  study pop: 
  sampling method: Probability Sample
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  last name: Hendrik Stragier, MD
  role: Principal Investigator
  affiliation: Ziekenhuis Oost-Limburg
  last name: Hendrik Stragier, MD
  phone: +3289325277
  email: hendrik.stragier@zol.be
  facility: 
  status: Recruiting
  contact: 
  country: Belgium
  responsible party type: Sponsor
  mesh term: Stroke
  mesh term: Ischemic Stroke
  mesh term: Subarachnoid Hemorrhage
  mesh term: Hemorrhagic Stroke
  mesh term: Hemostatic Disorders
  mesh term: Blood Coagulation Disorders
  mesh term: Ischemia
  mesh term: Hemorrhage
  sharing ipd: No